BioSpace News Archive

Sensorion a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces that its Annual Financial Report for the year ending December 31, 2022, is available to the public and filed with the French financial market authority.

Bioretec Ltd, a pioneer in bioresorbable orthopedic implants, has announced receiving the market authorization of the U.S. Food and Drug Administration for its pioneering RemeOs™ trauma screw to be used for healing of bone fractures aligned with the clinical trial.

Molecure S.A. a clinical stage biotechnology company that uses its world leading medicinal chemistry and biology capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate unexplored protein and RNA targets to treat multiple incurable diseases, announces full year results for the period ended 31 December 2022.

Poolbeg Pharma Plc a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, is pleased to announce its audited results for the year ended 31 December 2022.

Selvita S.A. one of the largest CRO companies in Europe has published a full-year report for 2022.

Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, reported financial results for the full-year ended December 31, 2022, and provided a corporate update.

Galderma will be presenting the latest data from the Sculptra® Cheek Wrinkle and Alluzience® STAR studies at the 21st Aesthetic & Anti-Aging Medical World Congress, taking place in Monaco, from March 30 to April 1, 2023.

The shareholders in Swedish Orphan Biovitrum AB Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting, to be held on Tuesday, 9 May 2023 at 15.00 at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.

Gandeeva Therapeutics, Inc. announced the initiation of a research collaboration with Moderna Inc. to explore applications of Gandeeva’s differentiated technology platform for a Moderna program.

Rockwell Medical, Inc. announced financial and operational results for the three months and full-year ended December 31, 2022.